Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02557321




Registration number
NCT02557321
Ethics application status
Date submitted
20/09/2015
Date registered
23/09/2015
Date last updated
21/11/2023

Titles & IDs
Public title
PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma
Scientific title
A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma
Secondary ID [1] 0 0
PV-10-MM-1201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Melanoma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Malignant melanoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - 0.1 mg/kg epsi-gam or placebo (6:2)
Treatment: Drugs - PV-10
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - 0.3 mg/kg epsi-gam or placebo (6:2)

Experimental: Phase 1b - PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)

Experimental: Phase 2 (Arm 1) - PV-10 (intralesional) and pembrolizumab (2 mg/kg every 3 weeks)

Active comparator: Phase 2 (Arm 2) - Pembrolizumab (2 mg/kg every 3 weeks)


Treatment: Drugs: 0.1 mg/kg epsi-gam or placebo (6:2)
administered as a single intravenous infusion on Day 1, infused over 30 minutes

Treatment: Drugs: PV-10
PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13

Treatment: Drugs: Pembrolizumab
Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)

Treatment: Drugs: 0.3 mg/kg epsi-gam or placebo (6:2)
administered as a single intravenous infusion on Day 1 infused over 30 minutes
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and tolerability of the combination regimen assessed by adverse events (AEs)
Timepoint [1] 0 0
Start of treatment until 4 weeks after final administration of PV-10
Primary outcome [2] 0 0
Progression Free Survival (PFS)
Timepoint [2] 0 0
Up to 24 months from initiation of study treatment
Secondary outcome [1] 0 0
Progression Free Survival (PFS)
Timepoint [1] 0 0
Up to 24 months from initiation of study treatment
Secondary outcome [2] 0 0
Objective Response Rate (ORR)
Timepoint [2] 0 0
Up to 24 months from initiation of study treatment
Secondary outcome [3] 0 0
Change in immune biomarkers
Timepoint [3] 0 0
Up to 28 weeks from initiation of study treatment
Secondary outcome [4] 0 0
Overall Survival (OS)
Timepoint [4] 0 0
24 months from initiation of study treatment for last subject randomized
Secondary outcome [5] 0 0
Safety and tolerability of the combination regimen assessed by adverse events (AEs)
Timepoint [5] 0 0
Start of treatment until 4 weeks after final administration of PV-10

Eligibility
Key inclusion criteria
1. Age 18 years or older, male or female.
2. Histologically or cytologically confirmed diagnosis of melanoma.
3. Stage IV or Stage III (unresectable, in-transit or satellite) melanoma.
4. At least 1 Injectable Lesion (i.e., cutaneous, subcutaneous, soft tissue, superficial nodal or palpable nodal lesion with longest diameter at least 5 mm that is suitable for injection with PV-10).
5. A minimum of 1 measurable Target Lesion that can be accurately measured by calipers, computed tomography (CT) or magnetic resonance imaging (MRI) consisting of at least one of the following:

* at least one cutaneous lesion (each lesion = 10 mm longest diameteror up to 5 lesions in aggregate having a sum of longest diameters = 10 mm); and/or
* at least one subcutaneous or soft tissue lesion (each lesion = 10 mm in longest diameter by CT or MRI); and/or
* at least one nodal lesion (each lesion = 15 mm in short axis diameter by CT or MRI); and/or
* at least one visceral lesion (each lesion = 10 mm in longest diameter by CT or MRI).
6. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-1.
7. Clinical Laboratories:

* absolute neutrophil count (ANC) = 1.5 x 109/L and platelet count =100 x 109/L
* estimated creatinine clearance (CrCl, by Cockcroft-Gault formula) or estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73 m2
* total bilirubin = 3 times the upper limit of normal (ULN)
* aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) = 5 times the upper limit of normal (ULN)
8. Thyroid function abnormality = Common Toxicity Criteria for Adverse Effects (CTCAE) Grade 2.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Untreated or clinically active melanoma brain metastases.

* Subjects with = 3 brain metastases and each = 1 cm size that were treated with either surgical resection and/or radiation therapy are eligible for study participation provided (a) there is no evidence of progressive central nervous system (CNS) disease on brain imaging at least 30 days after definitive treatment and (b) the subject is not taking prednisone at >10 mg or equivalent daily.
* Subjects with > 1 cm or > 3 in number treated brain metastases are eligible for study participation provided (a) there is no evidence of progressive CNS disease on brain imaging at least 90 days after treatment with surgery and/or radiation therapy and (b) if the subject is not taking prednisone at >10 mg or equivalent daily.
2. Prior treatment with PV-10 or any checkpoint inhibitor; however, subjects (a) who have failed to achieve a complete or partial response within 24 weeks following initiation of checkpoint inhibition or (b) who progressed after more than 12 weeks of checkpoint inhibition are eligible for study participation in the Phase 1b Expansion Cohort 1 without washout period for checkpoint inhibition.
3. Other prior cancer therapy or anti-cancer vaccine within the lesser of 4 weeks or 5 half-lives before initial study treatment.
4. Known sensitivity to any of the products or components to be administered during dosing.
5. Concurrent or Intercurrent Illness:

* History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis, vasculitis, or other systemic autoimmune disease.
* Evidence of clinically significant immunosuppression.
* Impaired wound healing or other extremity complications due to severe or uncontrolled diabetes mellitus in subjects whose Injectable Lesions are located in an extremity.
* Severe peripheral vascular disease (i.e., severe claudication [pain occurring after less than 200 meters of walking], rest pain, ischemic ulceration or gangrene) in subjects whose Injectable Lesions are located in an extremity.
* Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject's safety or compliance or interfere with interpretation of study results.
* Uncontrolled thyroid disease or cystic fibrosis.
* Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders.
* Malignancy other than melanoma within 2 years of enrollment except for: adequately treated (i.e., with curative intent) basal or squamous cell carcinoma, in situ carcinoma of the cervix, in situ ductal adenocarcinoma of the breast, in situ prostate cancer, or limited stage bladder cancer.
6. Pregnancy:

* Female subjects who are pregnant or lactating.
* Female subjects who have positive serum pregnancy test taken within 14 days of initiation of study treatment.
* Female subjects of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) who are not using highly effective contraception (e.g., oral contraceptives, intrauterine devices, double barrier methods such as condoms and diaphragms, abstinence or equivalent measures).
* Male subjects who are unwilling to use acceptable method of effective contraception.
7. Subjects unable to comprehend and give informed consent are excluded.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/10/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/04/2025
Actual
Sample size
Target
Accrual to date
Final
50
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
New Hampshire
Country [3] 0 0
United States of America
State/province [3] 0 0
Oregon
Country [4] 0 0
United States of America
State/province [4] 0 0
Pennsylvania
Country [5] 0 0
United States of America
State/province [5] 0 0
Texas

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Provectus Biopharmaceuticals, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Eric Wachter, Ph.D.
Address 0 0
Provectus Pharmaceuticals, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Eric Wachter, Ph.D.
Address 0 0
Country 0 0
Phone 0 0
865-769-4011
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT02557321